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Observing Huntington’s Disease: the European
Huntington’s Disease Network’s REGISTRY
September 28, 2010 · Huntington Disease
Background: Huntington’s disease (HD) is a rare triplet repeat (CAG) disorder. Advanced, multi-centre, multi-national
research frameworks are needed to study simultaneously multiple complementary aspects of HD. This includes the
natural history of HD, its management and the collection of clinical information and biosamples for research. 
Methods: We report on cross-sectional data of the first 1766 participants in REGISTRY, the European Huntington’s
Disease Network’s (EHDN), multi-lingual, multi-national prospective observational study of HD in Europe. Data
collection (demographics, phenotype, genotype, medication, co-morbidities, biosamples) followed a standard protocol. 
Results: Phenotype, and the HD genotype, of manifest HD participants across different European regions was similar.
Motor onset was most common (48%) with a non-motor onset in more than a third of participants. Motor signs
increased, and cognitive abilities and functional capacity declined as the disease burden (CAGn-35.5) X age)
increased. A life-time history of behavioural symptoms was common, but the behavioural score was not related to
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disease burden. One fifth of participants had severe psychiatric problems, e.g. suicidal ideation and attempts, and/or
irritability/aggression, with psychosis being less common. Participants on anti-dyskinetic medication had a higher
motor and lower cognitive score, were older, and more prone to physical trauma. A higher motor and a lower cognitive
score predicted more advanced disease. 
Conclusions: The unparalleled collection of clinical data and biomaterials within the EHDN’s REGISTRY can expedite
the search for disease modifiers (genetic and environmental) of age at onset and disease progression that could be
harnessed for the development of novel treatments.
Huntington’s disease (HD) is an autosomal dominant neurodegenerative disorder caused by a CAG repeat expansion
in the HTT gene. HD usually manifests in adult life, causing motor impairments, cognitive decline and
behavioural/psychiatric alterations [1] . HD is devastating and inevitably fatal; currently, no disease-modifying
treatment is established [2] .
Historically, the study of HD has benefited strikingly from multi-centre research initiatives, typified by the international
collaborative effort that identified the causative CAG repeat expansion in the HTT gene in 1993 [3] . Rapid advances in
molecular and cellular biology and genetics have produced a wealth of insights at the molecular level [4] . Much effort
at present is focused on identifying therapeutic targets and developing treatments that may delay onset of the disease,
or slow down or stop the progression of HD once it manifests.
With a prevalence of 5-8/100 000, manifest HD is relatively rare. Thus we need advanced, multi-centre, multi-national
research frameworks that allow us to study simultaneously multiple complementary aspects of HD. This includes the
natural history of HD, its management and the collection of clinical information and biosamples for research. The
European Huntington’s Disease Network (EHDN; www.euro-hd.net), established in 2004, is a collaborative network of
HD researchers, HD clinicians, people affected by HD, and their relatives across 18 European countries. It strives to
lay the foundations on which to advance knowledge about HD, how to optimally assess disease progression and
factors that modify the phenotype. This initiative aims to develop new symptomatic therapies, and provide the
infrastructure to test rapidly putative disease-modifying treatments in a multi-centre, multi-national setting with the
ultimate goal of improving the quality of life of people affected by the disease [5] .
In the present paper we report on cross-sectional enrolment data of a first cohort of participants in REGISTRY,
EHDN’s core observational study. REGISTRY is a multi-centre, prospective observational study with annual follow-up
visits that enrols manifest and pre-manifest HD expansion mutation carriers, individuals at risk of HD, non-mutation
gene carriers, and controls (no family history of HD). In the present study, we assessed the HD genotype and
phenotype across different European regions. We evaluated the phenotype and its variability in relation to CAG repeat
length and age as key biological factors; and European region, treatment modality and co-morbidity as environmental
factors. Finally, we examined potential predictors of functional capacity in domains relevant to daily life.
Participants
This report is based on monitored data from the enrolment visit of the first 1766 participants (98% Caucasians) in 66
study sites from 13 European countries within the European Huntington’s Disease Network (EHDN).
Participants gave informed written consent according to the International Conference on Harmonisation-Good Clinical
Practice (ICH-GCP) guidelines ( http://www.ich.org/LOB/media/MEDIA482.pdf ). For participants who lacked capacity
to consent study sites adhered to country-specific guidelines for obtaining consent. Minors assented with both parents
consenting for them. Ethical approval was obtained from the local ethics committee for each study site contributing to
REGISTRY.
Study design
Data collection followed a standard protocol (Table 1) using electronic case report forms available in Czech, Danish,
Dutch, English, Finnish, French, German, Italian, Norwegian, Polish, Portuguese, Spanish, and Swedish. At each
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centre, clinicians with long standing experience in HD took a careful history and examined patients clinically; motor,
psychiatric and cognitive signs were scored using the Unified Huntington’s Disease Rating Scale (UHDRS) [6] .
Assessments were complemented by self-rating scales that probed mood, quality of life and health economics (for an
overview and references see Table 1). Disease stage was derived from the Total Functional Capacity (TFC) scores [7]
.
Table 1. The complete REGISTRY assessment protocol
General Medical History (medical, disease, psychiatric)
Demographics (Fixed & Variable)
Comorbid conditions
Concomitant medication
Family History
CAG
Clinicalassessment UHDRS ’99 Motor, TFC, Functional [6]
UHDRS ’99 Behaviour [6]
Becks Depression Inventory [8]
Hamilton Depression Rating Scale [9]
Cognitive
assessments
UHDRS ’99 Cognitive (verbal fluency, symbol digit modality test, colour naming, word reading,
interference) [6]
Quality of Life SF-36 [10]Caregiver Burden Inventory [11]
Health economics Client Service Receipt Inventory [12]
Biosample
collection
30 ml blood, 30 ml urine
All participants were assigned a 9-digit pseudonym created using a secure one-way hash algorithm. No identifying
data were stored on the EHDN server. Data was entered on-line using an electronic web-based data capture system (
www.euro-hd.net ) where a username determines access rights within the web portal. No identifying data were stored
on the EHDN server. Entries for medication were coded according to the Anatomical Therapeutic Chemical (ATC)
classification (www.whocc.no/atcddd), and co-morbidities were coded according to ICD-10. Data entry onto the
webportal was subject to automatic plausibility checks. In addition, study site raters were annually trained, assessed
and certified to reduce inter- and intra-rater variability. Following data entry data were monitored on-line and on-site by
monitors fluent in the language of the contributing study site. Data monitoring adhered to the principles laid out in ICH-
GCP.
Biosample collection
Blood was collected and shipped to BioRep at room temperature for genetic analysis and lymphoblastoid cell line
creation (BioRep, Milan, Italy) [13] [14] . DNA was extracted [15] , and HTT gene CAG repeat length was analysed
(PCR amplification followed by capillary electrophoresis using the MegaBace Fragment Profiler Software from General
Electric, Buckinghamshire, UK [16] [17] . A second, independent, accredited laboratory in Tübingen, Germany,
duplicated CAG repeat analyses (Applied Biosystems, CA, USA). Mid-stream urine samples were collected for
biomarker studies. DNA and urine were stored at -80°C.
Data analyses
Descriptive statistics were calculated for quantitative variables and frequency counts by category for qualitative
variables. Confidence intervals were calculated where appropriate. If not stated otherwise, these intervals were two-
sided and provided 95% confidence. For qualitative variables Chi² tests or Fisher’s exact tests were used, for
quantitative variables t-tests, Kruskal-Wallis tests (global) and Wilcoxon-rank-sum-tests (pairwise comparisons) were
used as appropriate. All tests were performed two-sided where p-values below 5% were regarded as statistically
significant.
Cohen’s kappa examined the agreement of the laboratories measuring the CAG repeat lengths [18] .
Linear regression analysis with F-test examined which factors influence continuous variables. Logistic regression
evaluated factors explaining absence/presence of suicidal attempts. Multinomial logistic regression was performed to
select factors important for the prediction of the disease stage in this cross-sectional analysis and to perform receiver
operating characteristic (ROC) analysis to evaluate the predictive value of important factors for the disease stage.
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Calculations were performed using R software (version 2.7.1, R Development Core Team (2008)) and NCSS 2007
(NCSS, Kaysville, Utah, USA).
Participants and genotype
Of 1766 participants, 1540 had manifest HD, 226 were pre-manifest gene mutation carriers defined as carrying the HD
gene mutation and having a diagnostic confidence score of less than 4 on the UHDRS motor scale [6] . The median
estimated age at onset in manifest HD participants was 43 years (range 10-87 years). In 795 patients (45%) the gene
was inherited from the mother and in 710 (40.2%) from the father. In 25 participants (1.5%), there was no known family
history, and in 234 (13.3%) the information was missing. Thirty-two participants (2.1%) had a juvenile-onset (before the
age of 20, [19] ), and 96 (5.4%) had a late-onset of HD (above the age of 60).
Clinical phenotype
We analysed 1468 participants from 13 countries where a complete set of demographic data (age, sex), CAG repeat
length (large allele), UHDRS motor score and TFC were all available (Table 2). Numbers of participants from individual
countries were too low for meaningful statistical analyses. For this reason we arbitrarily collapsed participants by
geographical region. 514 were from Central Europe (Germany, Austria, Switzerland, Netherlands, Belgium), 110 were
from Northern Europe (Denmark, Norway, Finland), 457 were from Southern Europe (Italy, Spain, Portugal), 334 were
from the United Kingdom, and 53 were from Poland. 784 were female. 1280 had manifest HD, and 188 had
premanifest HD (Table 2).
Table 2. Clinical and genetic data from REGISTRY participants. Demographic, clinical and genetic data from
REGISTRY participants. All participants (apart from Polish) with core data set (age, CAG repeat larger allele, UHDRS
motor score, TFC).  Germany, Austria, Switzerland, Netherlands, Belgium;  Denmark, Norway, Finland;  Italy, Spain,
Portugal. CAG repeat information was from BioRep when both local and BioRep were available. Demographic and
CAG repeat information is from all participants with core data (Central European n=514; Nordic n=110; Southern
European n=457; UK n=286). TFC, disease stage and UHDRS motor score are from all manifest participants (Central
European n=445; Nordic n=92; Southern European n=410; UK n=286).
All Central
European 
Northern
European 
Southern
European 
UK
Age (median, range) 49 (10-
93)
47 (20-87) 50 (23-93) 49 (11-83) 49 (17-
85)
Male:female 0.87 0.85 1.08 0.92 0.79
CAG (median, range) 44 (36-
90)
43 (38-65) 42 (36-51) 44 (36-90) 43 (37-
85)
Reduced penetrance range
(%)
45 (3.1) 9 (1.8) 11 (10) 10 (2.2) 12 (3.6)
Premanifest (% total) 188
(12.8)
69 (13.4) 18 (16.4) 47 (10.3) 48 (14.4)
UHDRS motor 34 (0-
106
31 (0-105) 29 (2-94) 37.5 (2-106) 35 (0-
101)
TFC 8 (0-13) 8.2 (0-13) 8.1 (0-13) 7.5 (0-13) 7.4 (0-
13)
Stage 1 (%) 389
(30.4)
166 (37.3) 25 (27.2) 130 (31.6) 58 (20.3)
Stage 2 (%) 405
(31.6)
136 (30.6) 37 (40.2) 100 (24.3) 119
(41.6)
Stage 3 (%) 333 (26) 94 (21.1) 24 (26.1) 118 (28.7) 80 (28)
Stage 4/5 (%) 154 (12) 49 (11) 6 (6.5) 63 (15.3) 29 (10.1)
Investigators estimated that 615 (48%) participants with manifest HD had motor signs at onset while 251 (19.6%) had
a psychiatric onset, 107 (8.4%) first had cognitive signs and 169 (13.2%) had a mixed onset. Information was missing
Results
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from 125 (9.8%). 503 participants (39.3%) had a life-time history of severe psychiatric signs (psychosis, aggression
and suicidal ideation) – 126 (9.8%) participants had two or more severe psychiatric signs and 21 participants (1.6%)
had all three. 151 (11.8%) had a life-time history of delusions and/or hallucinations, 244 (19.1%) had disruptive or
aggressive behaviour and 255 (19.9%) had suicidal ideation or suicide attempts with a total of 90 recorded suicide
attempts in all stages of HD (stage 1: 14 (15.6%); stage 2: 27 (30%); stage 3: 29 (32.2%); stage 4/5: 20 (22.2%)). A
high mood subscore of the behavioural score was highly predictive of a suicide attempt (logistic regression analysis, z-
test=3.84, p=0.0001) whereas motor, cognitive or the behavioural subscores for apathy, compulsions, psychosis or
irritability were not.
The majority of participants who underwent behavioural assessment had behavioural abnormalities (depression,
apathy, irritability) in addition to motor signs (694 (86.6%) while 107 (13.4%) had none.
Co-morbid conditions and medication
A co-morbid condition, interfering morbidity or previous intervention was recorded in 706 participants (40.0%). Most
common were essential primary hypertension (ICD-10 code I10, 133 participants), pure hyper-cholesterolaemia
(E78.0. 62) asthma (J45, 48), diabetes mellitus (E10-E14, 26), hypertrophy of prostate (N40, 27), unspecified arthritis
(M13.9, 25) and unspecified hypothyroidism (E03.9, 24). Co-morbid conditions were then grouped revealing that 67
participants (3.8%) had ‘neoplasms’ (ICD-10 C and D), 187 (10.6%) had ‘endocrine disorders’ (ICD 10 E), 227 had
‘cardiovascular disorders’ (ICD-10 G and I), and 148 suffered physical ‘trauma’ as interfering morbidity (ICD-10 S).
‘Trauma’ was common across all stages but was less frequent in stage 4/5 (stage 1: 50 (33.8%), stage 2: 43 (29.1%),
stage 3: 30 (20.3%), stage 4/5: 12 (8.1%)).
Most participants were taking medication (1022, 57.9%). The most commonly taken medications are listed in Table 3
with their respective medication class in Table 4.
Table 3 . The most commonly prescribed drugs. A total of 3074 concomitant medications were recorded (ATC:
Anatomical Therapeutic Chemical)
Medication ATC code n Typical indications
Tiapride hydrochloride N05AL03 148 Chorea/hyperkinesias
Olanzapine N05AH03 133 Chorea/dyskinesia/aggression/psychosis
Risperidone N05AX08 121 Chorea/Dyskinesia/aggression/psychosis
Citalopram hydrobromide N06AB04 120 Depression/irritability
Paroxetine hydrochloride N06AB05 120 Depression/irritability
Haloperidol N05AD01 109 Chorea
Clonazepam N03AE01 79 Anxiety
Amantadine hydrochloride N04BB01 76 Chorea/dyskinesia
Mirtazapine N06AX11 75 Depression/insomnia
Tetrabenazine N07XX06 69 Chorea/dyskinesia
Lorazepam N05BA06 54 Anxiety
Sulpiride N05AL01 46 Chorea/dyskinesia/irritability
Table 4. Medication classes. We defined 5 groups of medication. Medications to treat motor signs (‘anti-dyskinetics’)
comprised anti-psychotics (N05AA01), tetrabenazine (N07XX06) and anti-parkinsonian medications (N04A, N04B);
‘anti-depressants’ comprised medications coded as anti-depressants (N06A, N06C), anxiolytics (N05B, N05C), lithium
(N05AN01), and anti-epileptics (N03A) where the indication was ‘depression’ or ‘mood stabilisation’. ‘Anti-dementia’
included medications coded as anti-dementia (N06D) or psychostimulants (N06B). ‘Nutritional supplements’ were all
medications with ATC codes A11, B03BB01, C10AX06, H05BA01, N06BX13, or C01EB05. All other medications were
combined as ‘others’. In manifest participants, ‘anti-dyskinetics’ were used more frequently in Southern Europe and
Poland (p<0.0001), and in Southern Europeans ‘anti-depressants’ were used somewhat more frequently than in other
regions (p<0.0001). Use of all other medications was similar across regions. ATC: Anatomical Therapeutic Chemical
Medication class All manifest
participants
Central
European
Northern
European
Southern
European
UK Poland
Anti-dyskinetic 607 (39.3%) 199 (37.2%) 18 (18%) 263 (56%) 94
(23.9%)
33
(70%)
Anti-depressant 702 (45.6%) 203 (38.1%) 39 (39%) 270 (57.7%) 169 21
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(43.1%) (45.7%)
Anti-dementia 65 (4.2%) 45 (8.4%) 6 (6%) 12 (2.6%) 0 2 (4.3%)
Nutritional
supplements
171 (11.1%) 78 (14.4%) 12 (12%) 58 (12.4%) 16
(4.1%)
7
(14.9%)
Other 335 (21.8%) 142 (26.6%) 19 (19%) 76 (16.2%) 79
(20.2%)
19
(40.4%)
Genotype and phenotype across European regions
Across contributing European regions gender distribution was similar (Table 2; χ  = 2.5273, n.s.). CAG repeat length
differed statistically between regions (p<0.05 and p<0.0001, respectively); participants from Northern Europe had
slightly shorter repeat lengths than those from Central Europe (p<0.0001), Southern Europe (p<0.0001) and the UK
(p=0.0001, Table 2) probably because there were no Nordic participants with very large CAG repeat length
expansions.; Southern European participant’s CAG repeat lengths were slightly larger than those of participants from
Central Europe (p<0.01) or from the UK (p<0.01). Central European participants were younger than participants from
Southern Europe (p=0.01) and the UK (p<0.05), and UHDRS motor scores were also similar apart from Southern
European participants who had a slightly higher motor score than Central Europeans (p<0.0001), Northern Europeans
(p<0.01) and the UK (p<0.05), with no further differences observed between other regions (Table 2). Central
Europeans were slightly less advanced in HD than Southern Europeans (p=0.01) and UK participants (p<0.01).
Association of phenotype with disease burden
We related the severity of the clinical signs across three domains of HD (motor, behaviour (n=801), cognition (n=676))
to a measure of the biological disease burden calculated from a participant’s age and CAG repeat length ((CAG 
-35.5) X age = disease burden: [20] . UHDRS motor score increased in severity with increasing disease burden (linear
regression, adjusted R  =0.19, p<0.0001, Figure 1A) while cognitive composite score (UHDRS total correct for letter
fluency, symbol digit modalities test and Stroop subscores for word reading, colour naming and interference; linear
regression, adjusted R  =0.1224, p<0.0001 Figure 1B) or equally weighted scores (adjusted R  =0.1245, p<0.0001)
and function declined (linear regression, adjusted R  =0.1172, p<0.0001, Figure 1C). In contrast, there was no linear
association of the total behavioural score, or the subscores mood (depression, low self esteem, anxiety, freq*severity),
psychosis (delusions and hallucinations, freq*severity), irritability/aggression (disruption, aggression and
perseverations, freq*severity) or compulsions (freq*severity) with disease burden (Figure 1D). Only apathy
(freq*severity) was very weakly associated with disease burden (adjusted R  =0.01, p=0.0024).
2
4
n
2
2 2
2
2
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Fig. 1: Association of UHDRS domain score, or TFC, with disease burden. A. Linear increase of motor score with
increasing disease burden. B. Linear decrease of cognitive score with increasing disease burden. C. Linear
decline of TFC with increasing disease burden. D. No linear association of behavioural score with disease burden.
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The variability of the phenotype
The amount of variability of the scores in the three symptom domains of HD explained by disease burden alone was
low. We therefore assessed the extent to which biological (‘age’, ‘CAG repeat length’) or environmental factors
(‘region’, ‘medication’, ‘co-morbidity’) contributed to this variability. Overall, 23% of the variation of the motor score was
explained by the factors in the final multiple linear regression model (p<0.0001, adjusted R  =0.23). A higher motor
score was associated with the use of ‘anti-dyskinetics’, with the presence of ‘trauma’, with increasing age and
increasing CAG repeat lengths (Figure 2). For the behavioural score, 12% of the variation of the behavioural score
was explained by the factors in the final model (p<0.0001, adjusted R  =0.12). The use of ‘anti-depressants’ and ‘anti-
dyskinetics’, and the presence of endocrine co-morbidity, was associated with a higher behavioural score. Overall,
24% of the variation of the composite cognitive score was explained by the factors in the final model (p<0.0001,
adjusted R  =0.24), and 25% of the cognitive score where items were weighted equally (p<0.0001, R  =0.25). A
higher cognitive score was associated with the use of ‘nutritional supplements’ and ‘other medications’ whereas a
lower score was associated with the use of ‘anti-dyskinetic’ medication, increasing CAG repeats and age.
2
2
2 2
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Fig. 2: Treatment with anti-dyskinetic medications. Participants on medication for motor signs (‘treated’ with anti-
dyskinetic, dopamine depleting or dopaminergic) had a higher motor score than un-treated participants (Mann-
Whitney U test, p
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Total functional capacity
Finally, we investigated whether changes in the scores in the three domains, biological (‘age’, ‘CAG repeat length’) or
environmental factors (‘region’, ‘medication’, ‘co-morbidity’) predicted disease stage. To this end we used multi-nomial
logistic regression analysis with the disease stage as dependent variable and domain scores, biological and
environmental factors as independent variables. For cognitive scores we used the composite score, an equally
weighted score or the subscores. In the final model, the factors ‘motor score’, ‘region’ and ‘cognitive score’ explained
28% of the variability of disease stage. The results were similar when using the composite cognitive score or an
equally weighted cognitive score, or the symbol digit test as single subscore. Internal validation using the same data
correctly classified about 59% of all participants across all disease stages compared with the actual disease stages
(table 5). The ROC analysis of the final model accurately classified more than 80% for each individual stage except for
disease stage 2 with an accuracy of about 75% (Table 5 and Figure 3).
Table 5. Comparing the accuracy of multinomial logistic regression analyses with different types of cognitive
score. Comparison of the performance of different multinomial logistic regression models with the total sum cognitive
score, equally weighted cognitive score or symbol digit subscore.
Accuracy
Cognitive score Proportion correct
(%)
Disease
Stage 1
Disease
Stage 2
Disease
Stage 3
Disease Stage
4/5
Cognitive score 58.9 84.8 73.9 82.6 86.2
Cognitive equally
weighted
59.5 84.8 74.1 82.4 86.5
Subscores
(symboltest)
58.5 84.5 74.2 81.9 83.1
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Fig. 3: Receiver operating characteristic (ROC) curves plot the sensitivity versus (1-specificity) for classifying each
disease stage (stages 1-4/5).
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We report on the first cross-sectional data cut of REGISTRY, EHDN’s large scale multi-centre multi-national
prospective observational study of HD.
The proportions of gene mutation carriers, manifest participants, and among these juvenile and late-onset participants,
were similar across regions. Age and gender distribution, CAG repeat length, and the severity of the core symptom
domains of HD (motor, cognitive, behaviour) as well as functional capacity were broadly comparable across different
European regions. Ethnicity may influence the prevalence of HD; in Japanese for instance, and possibly in Sub-
Saharan Africans, HD may be much rarer than in Caucasian populations [21] . Whenever HD manifests, however, the
phenotype and progression of the disease appear similar. This is in agreement with data from Venezuela where the
phenotype and CAG repeat length expansions are similar to participants from North America or Europe [22] .
Europeans taking part in this study were mainly Caucasian. Despite sharing much of their genetic makeup, extensive
SNP maps suggest that Northern and Southern European populations differ to some extent [23] . This suggests that
the CAG repeat expansion in the HTT gene influences the phenotype in a similar way across Europe. However,
environmental influences may differ, one example being medication with more than half of all manifest participants
taking medication. Investigators prescribed similar medication classes. Southern European and Polish investigators,
however, used anti-dyskinetic medication more frequently than investigators in other regions.
Collapsing contributing countries into regions was somewhat arbitrary. In the future, with larger numbers of participants
we could re-examine whether extracting any one country from a regional bin leads to a different finding. Any difference
could reflect different genetic, or environmental, influences within that given country. However, the similar CAG repeat
genotypes and phenotypes across European regions imply that one can conduct treatment trials across Europe
without the need for stratification according to country. Considering the potential scale of these trials, this is
encouraging.
The evolution of the phenotype, and its variability
Since the phenotype was similar in European regions we evaluated the evolution of HD in the whole cohort of
participants. Good evidence suggests that biological factors, in particular CAG repeat length and age, contribute to
when first symptoms manifest and how HD evolves biologically [20] [22] [24] [25] . Thus we related the evolution in
three clinical domains, i.e. motor, cognitive and behaviour, to the continuous measure of biological disease burden that
is linearly associated with the neuropathological disease stage and is closely related to striatal volumes [20] . In
contrast to clinical ratings of disease evolution, such as TFC, disease burden consists of unambiguous variables. Our
data indicate that motor score and TFC increased and cognitive score decreased monotonically with an increasing
biological disease burden. This is in accord with longitudinal observations of clinical evolution alone [26] . In contrast,
with the exception of the apathy subscore, behavioural scores were not associated with disease burden. The effective
treatment of many behavioural problems, e.g. depression, irritability, aggression or psychosis may suggest these
behaviours are episodic rather than progressive. If left untreated, however, it is possible that symptoms such as e.g.
irritability may progress, and it is likely that some behaviours do reflect degenerative neuropathological processes. The
treatment of apathy proves much more difficult; sometimes apathy may improve with successful treatment of a
depressive episode or psychosis suggesting it may be part of several different underlying psychopathologies including
depression and, as a negative syndrome, psychosis [27] [28] . Current concepts of what constitutes apathy, and how
to diagnose it, have recently been reappraised [27] [28] . Since apathy is currently not well defined, and its origins may
be quite different, it is perhaps not surprising that the association of apathy with disease burden is not as strong as
that of motor or cognitive signs.
Taken together, these data suggest that the clinical evolution of HD, and the subsequent impediments in daily life,
reflects the neuropathological changes accruing over time. The relation of clinical findings to biological factors extends
previous descriptions of the clinical evolution of HD [26] . However, overall, the variability of the clinical scores
explained by the disease burden score was moderate. One explanation might be that CAG repeat length and age are
only two of many biological factors determining the evolution of HD [22] . Environmental factors, e.g. medication, may
also contribute to the variability. The use of anti-dyskinetic medication for instance influenced all three domains since it
was associated with a higher motor score, a higher behavioural score and a lower cognitive score.
Discussion
14/7/2018 Observing Huntington’s Disease: the European Huntington’s Disease Network’s REGISTRY – PLOS Currents Huntington Disease
http://currents.plos.org/hd/article/observing-huntingtons-disease-the-european-huntingtons-disease-networks-registry-3/ 13/18
The strength of our study is the large number of participants with data collected across Europe following the same
study protocol. We demonstrate that such studies can be conducted effectively across different countries and multiple
languages. In addition, investigators are regularly trained and certified to improve data quality. REGISTRY, unlike
many observational clinical research initiatives, engaged data monitoring based on the principles of ICH-GCP.
Participating sites are visited regularly by a team of trained monitors in order to ensure the plausibility and accuracy of
the data, and to promote adherence to the study protocol and its procedures. Data monitoring is not a prerequisite for
cohort studies, but it is an investment to enhance the collection of more robust and reliable data.
All predictions on the evolution of the HD phenotype from the present cross-sectional analyses need to be tested
further in an appropriate longitudinal follow-up design that examines relative effects over time. The REGISTRY
database continues to expand and should allow such studies in the very near future. In addition, given more time and
repeated visits, missing data can be resolved such that both the proportion and the total number of complete data sets
increases. This includes the length of time and dosing regime of participants on medication, which were not taken into
account in the present study.
A separate concern relates to whether the sample is truly representative. The database necessarily reflects the HD
population who live near to neurological HD services, which are predominantly located in cities. The present cohort
may also have been biased towards excluding individuals with active, e.g. psychiatric problems leaving less time to
participate in the study. Late-stage participants were also under-represented illustrating their difficulties in attending
out-patient clinic and the limitations using currently available scales.
Many studies of HD, including REGISTRY, rely on assessment scales that depend on subjective impressions of
clinicial ratings. Rating scales themselves may also differ in quality and thus introduce data variability. The UHDRS
has not (yet) been evaluated using analytical methods such as the Rasch analysis or Item Response Theory [29] ,
although such analyses are well under way. However, the variability of clinical signs and their ratings also underlines
the need to identify and validate better biomarkers of disease progression.
The unparalleled large collection of clinical data and biomaterials in REGISTRY will enable research projects to be
conducted on a scale that has not previously been possible. The initiative will expedite the search for disease
modifiers (genetic and environmental) of age at onset and disease progression that could be harnessed for the
development of novel treatments, thus offering a promising new direction towards slowing down or preventing this
debilitating disease.
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